Physician profile
Boris Medvedovsky
NPI 1689833303
$1,458.36
in general payments reported to CMS, 2019-2025
27 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $283 · 2022: $127 · 2023: $347 · 2024: $399 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.62 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $216.19 | 2021-2024 | |
| Medtronic, INC. | $127.23 | 2022 | |
| Pfizer INC. | $109.82 | 2023-2024 | |
| Novo Nordisk INC | $106.82 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $97.95 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $97.41 | 2023-2025 | Austedo Xr, Austedo Xr |
| Amgen INC. | $91.18 | 2023-2025 | Evenity, Prolia, Prolia |
| Dexcom, INC. | $66.77 | 2023-2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $66.36 | 2024-2025 | Gemtesa |
| Lilly USA, LLC | $58.58 | 2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.20 | 2023-2024 | Xifaxan |
| Abbvie INC. | $42.05 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $35.09 | 2021 | |
| Azurity Pharmaceuticals, INC. | $31.95 | 2023-2024 | Horizant, Horizant |
| Ge Healthcare | $26.06 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $23.83 | 2024 | Cologuard Collection Kit |
| Shield Therapeutics INC | $23.28 | 2025 | |
| Eisai INC. | $20.53 | 2024 | |
| Opko Pharmaceuticals, LLC | $20.14 | 2021 | |
| Astellas Pharma US INC | $19.51 | 2023 | Veozah |
| Aurinia Pharma U.S., INC. | $19.38 | 2021 | |
| Glaxosmithkline, LLC. | $19.35 | 2024 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $19.05 | 2021 | |
| Akebia Therapeutics INC | $18.50 | 2021 | |
| Vifor Pharma, INC. | $18.34 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.52 | 2025 | Voquezna |
| Fresenius USA Marketing, INC. | $13.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Medvedovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.